Eliquis(apixaban)
Apixaban, Eliquis (apixaban) is a small molecule pharmaceutical. Apixaban was first approved as Eliquis on 2011-05-18. It is used to treat pulmonary embolism and venous thrombosis in the USA. It has been approved in Europe to treat arthroplasty, stroke, and venous thromboembolism. The pharmaceutical is active against coagulation factor X.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Apixaban, Eliquis (discontinued: Apixaban)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Apixaban
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ELIQUIS | Bristol Myers Squibb | N-202155 RX | 2012-12-28 | 2 products, RLD, RS |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| venous thrombosis | — | D020246 | I82.40 |
| pulmonary embolism | EFO_0003827 | D011655 | I26 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
422 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | 2 | 11 | 17 | 26 | 102 | 157 |
| Thrombosis | D013927 | — | — | 5 | 7 | 26 | 19 | 30 | 85 |
| Thromboembolism | D013923 | — | — | 7 | 15 | 8 | 17 | 40 | 84 |
| Venous thromboembolism | D054556 | EFO_0004286 | I74 | 6 | 14 | 7 | 15 | 31 | 70 |
| Hemorrhage | D006470 | MP_0001914 | R58 | 1 | 4 | 12 | 3 | 20 | 40 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | 11 | 7 | 21 | 39 |
| Embolism | D004617 | — | — | 3 | 3 | 13 | 5 | 16 | 38 |
| Venous thrombosis | D020246 | — | I82.40 | — | 3 | 17 | 8 | 12 | 38 |
| Pulmonary embolism | D011655 | EFO_0003827 | I26 | 3 | 2 | 11 | 4 | 10 | 29 |
| Ischemic stroke | D000083242 | — | — | 1 | 1 | 5 | 3 | 16 | 25 |
Show 57 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | — | — | 4 | — | 3 | 7 |
| Cerebral hemorrhage | D002543 | — | — | — | 2 | 4 | — | 1 | 7 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | 1 | — | 3 | 5 |
| Aortic valve stenosis | D001024 | EFO_0000266 | — | — | — | 3 | — | 2 | 5 |
| Wounds and injuries | D014947 | — | T14.8 | — | 1 | 1 | — | 2 | 4 |
| Intracranial thrombosis | D020767 | — | — | — | — | 3 | — | 1 | 4 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | 1 | — | 1 | 3 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | 2 | 1 | — | — | 3 |
| Myeloproliferative disorders | D009196 | — | D47.1 | — | 1 | 1 | — | 1 | 3 |
| Traumatic intracranial hemorrhage | D020198 | — | — | — | — | 3 | — | — | 3 |
Show 44 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 11 | 3 | — | — | — | 14 |
| Nephrotic syndrome | D009404 | EFO_0004255 | N04 | 3 | 1 | — | — | — | 3 |
| Nephrosis | D009401 | — | — | 3 | 1 | — | — | — | 3 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 1 | 1 | — | — | — | 2 |
| Replacement arthroplasty knee | D019645 | — | — | — | 1 | — | — | 1 | 2 |
| Spinal cord injuries | D013119 | EFO_1001919 | — | — | 1 | — | — | 1 | 2 |
| Female genital neoplasms | D005833 | — | — | — | 1 | — | — | 1 | 2 |
| Glioma | D005910 | EFO_0000520 | — | — | 1 | — | — | 1 | 2 |
| Fasting | D005215 | EFO_0002756 | — | 1 | 1 | — | — | — | 2 |
| Sinus arrhythmia | D001146 | — | — | — | 1 | — | — | — | 1 |
Show 21 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coagulation protein disorders | D020147 | — | — | 2 | — | — | — | 1 | 3 |
| Membranous glomerulonephritis | D015433 | EFO_0004254 | N03.2 | 1 | — | — | — | — | 1 |
| Peritoneal dialysis | D010530 | — | — | 1 | — | — | — | — | 1 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | 1 | — | — | — | — | 1 |
| Crohn disease | D003424 | EFO_0000384 | K50 | 1 | — | — | — | — | 1 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | 1 | — | — | — | — | 1 |
| Proteinuria | D011507 | — | R80 | 1 | — | — | — | — | 1 |
| Crush injuries | D000071576 | — | T14.8 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative hemorrhage | D019106 | — | — | — | — | — | — | 4 | 4 |
| Heart valve diseases | D006349 | EFO_0009551 | I08 | — | — | — | — | 3 | 3 |
| Postphlebitic syndrome | D011186 | — | I87.0 | — | — | — | — | 3 | 3 |
| Postthrombotic syndrome | D054070 | EFO_0007452 | I87.0 | — | — | — | — | 3 | 3 |
| Arterial occlusive diseases | D001157 | EFO_0009085 | — | — | — | — | — | 2 | 2 |
| Thrombophilia | D019851 | — | D68.59 | — | — | — | — | 2 | 2 |
| Postoperative complications | D011183 | — | — | — | — | — | — | 2 | 2 |
| Coronary disease | D003327 | — | — | — | — | — | — | 2 | 2 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 2 | 2 |
| Therapeutic chemoembolization | D016461 | — | — | — | — | — | — | 2 | 2 |
Show 37 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Apixaban |
| INN | apixaban |
| Description | Apixaban is a pyrazolopyridine that is 7-oxo-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide substituted at position 1 by a 4-methoxyphenyl group and at position 6 by a 4-(2-oxopiperidin-1-yl)phenyl group. It is used for the prevention and treatment of thromboembolic diseases. It has a role as an anticoagulant and an EC 3.4.21.6 (coagulation factor Xa) inhibitor. It is a pyrazolopyridine, a member of piperidones, a lactam and an aromatic ether. |
| Classification | Small molecule |
| Drug class | antithrombotics, blood coagulation factor XA inhibitors |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 503612-47-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL231779 |
| ChEBI ID | 72296 |
| PubChem CID | 10182969 |
| DrugBank | DB06605 |
| UNII ID | 3Z9Y7UWC1J (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Eliquis – Bristol Myers Squibb
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Eliquis – Pfizer
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Apixaban
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 18,183 documents
View more details
Safety
Black-box Warning
Black-box warning for: Apixaban, Eliquis
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
153,178 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use